Fibrotech is Granted US and Canadian Patents
News Mar 08, 2014
Fibrotech has announced that it has been granted patents in the USA and Canada relating to the Company’s proprietary novel anti-fibrotic compounds.
The US patent is entitled “Halogenated Analogues of Anti-Fibrotic Agents” and the Canadian patent is entitled “Therapeutic Compounds”. Both have been granted composition of matter claims.
Prof. Darren Kelly, CEO of Fibrotech commented: “We are poised to announce Phase I results for our lead product so the granting of these patents is timely and will help us greatly in ongoing partnering discussions.”
Fibrotech entered the clinic in 2013 with its lead product FT011 for diabetic nephropathy. Kidney failure in diabetes occurs as a result of kidney fibrosis (scarring). This fibrosis is in turn due to the long term damage from excessive sugar levels in the blood. The results from a Phase I trial of FT011 will shortly be released.
Professor Darren Kelly, CEO of Fibrotech will be attending BIOEurope Spring in Turin on 10th and 11th of March and will be happy to meet with interested journalists and other parties there.